Sumitomo Dainippon Pharma Co Ltd (4506)

1,325.0
-31.0(-2.29%)
  • Volume:
    1,500,500
  • Bid/Ask:
    1,325.0/1,328.0
  • Day's Range:
    1,322.0 - 1,355.0
  • Type:Equity
  • Market:Japan
  • ISIN:JP3495000006

4506 Overview

Prev. Close
1,356
Day's Range
1,322-1,355
Revenue
548.18B
Open
1,326
52 wk Range
1,271-2,363
EPS
139.37
Volume
1,500,500
Market Cap
526.41B
Dividend (Yield)
28.00
(2.06%)
Average Volume (3m)
1,132,859
P/E Ratio
9.73
Beta
1.01
1-Year Change
1.06%
Shares Outstanding
397,293,217
Next Earnings Date
26 Jan 2022
What is your sentiment on Sumitomo Dainippon Pharma Co Ltd?
or
Market is currently closed. Voting is open during market hours.

Sumitomo Dainippon Pharma Co Ltd Company Profile

Employees
6822
Market
Japan

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.